What is Zoetis acquiring and why is it significant?

Zoetis is acquiring Salar Topco AS, the parent company of Pharmaq AS, which is a leading global player in the aquatic animal health sector. This is significant because it represents a strategic move for Zoetis to expand its reach into the high-growth aquaculture market, diversifying its existing animal health portfolio.

How much is Zoetis paying for the acquisition and how will it be funded?

The aggregate cash purchase price is approximately $765 million, subject to adjustments for working capital and net indebtedness. Zoetis expects to fund the acquisition by borrowing under its existing revolving credit facility.

What are the key conditions for the acquisition to close?

The transaction is subject to customary closing conditions. These include the absence of a material adverse effect on TopCo, no legal prohibitions, accuracy of representations, compliance with covenants, and approval by shareholders of Seller AS holding at least two-thirds of its share capital and votes. Importantly, a majority of these shareholders have already committed to voting in favor.

Are there any changes to Zoetis's financing arrangements due to this acquisition?

Yes, Zoetis amended its revolving credit facility. This amendment allows for a temporary increase in the maximum permitted leverage ratio (to 4.25x from 3.50x) for a specified period following the consummation of a material acquisition like this one, providing financial flexibility.

ZTS 8-K: Material Agreements

Summary

Zoetis Inc. has entered into a definitive agreement to acquire the privately held Norwegian company, Salar Topco AS, which is the parent company of Pharmaq Holding AS, a leader in aquatic animal health. The acquisition is valued at approximately $765 million in cash, subject to customary adjustments for working capital and net indebtedness. Zoetis intends to finance this significant strategic acquisition through its existing revolving credit facility, indicating confidence in its liquidity and borrowing capacity. The deal is expected to close around November 10, 2015, pending standard closing conditions, including shareholder approval from Seller AS, which has already provided irrevocable undertakings to vote in favor. This acquisition represents a material expansion for Zoetis into the growing global aquaculture sector, a key area for animal health innovation and demand. The company also announced an amendment to its revolving credit facility, which provides flexibility for increased leverage ratios following a material acquisition like this one, ensuring continued financial maneuverability. Investors should view this as a strategic move to diversify and strengthen Zoetis's portfolio within the animal health market, particularly in a high-growth segment.

Key Highlights

1Zoetis Inc. to acquire Salar Topco AS (parent of Pharmaq AS), a leading global aquatic animal health company, for approximately $765 million in cash.
2The acquisition significantly expands Zoetis's presence in the growing aquaculture market.
3The transaction is expected to be funded through Zoetis's revolving credit facility.
4Closing of the transaction is anticipated on or about November 10, 2015, subject to customary closing conditions and shareholder approval.
5An amendment to Zoetis's revolving credit facility allows for temporary increased leverage ratios post-acquisition.
6Shareholders of Seller AS, representing over 2/3rds of capital and votes, have provided irrevocable undertakings to approve the transaction.
7Customary representations, warranties, and covenants are included in the Share Purchase Agreement, with specific survival periods for certain clauses.

Zoetis Inc. 8-K Report, Material Agreement (Nov 2, 2015)

Summary

Key Highlights

Frequently Asked Questions